Table 2.
Relation between Serum Level of IL-6 with Different Circulated Autoantibodies in Infected HCV Patients
| serum level of IL-6 | ||||||||
|---|---|---|---|---|---|---|---|---|
| N | Patients | N | Control | |||||
| Median | Min. – Max | P | Median | Min. – Max | p | |||
| Gender | 74 | 34.5 | 0.006* | 55 | 31 | 5.2 – 139.0 | 0.204 | |
| Male | 28 | 26.5 | 4.0 – 1086.0 | 48 | 26.8 | 3.7-100.4 | ||
| Female | 5.0-561.0 | |||||||
| ANA | ||||||||
| Less than 1:80 | 78 | 29.0 | 4.0 – 1086.0 | 0.483 | 98 | 29.65 | 3.7 – 139.0 | 0.69 |
| 1:80 | 18 | 32.0 | 6.0 – 1073.0 | 5 | 19.6 | 9.3 – 43.6 | ||
| 1:60 | 6 | 19.5 | 6.0 – 235.0 | 0 | - | |||
| AMA | ||||||||
| Less than 1:20 | 94 | 29.0 | 4.0 – 1086.0 | 0.515 | 103 | 29.3 | 3.7 – 139.0 | - |
| 1:20 | 5 | 27.0 | 6.0 – 987.0 | 0 | - | |||
| 1:40 | 3 | 224.0 | 29.0 – 431.0 | 0 | - | |||
| ASM | ||||||||
| Less than 1:20 | 85 | 29.0 | 6.0 – 1086.0 | 0.543 | 103 | 29.3 | 3.7 – 139.0 | - |
| 1:20 | 13 | 29.0 | 4.0 – 431.0 | 0 | - | |||
| 1:40 | 3 | 29.0 | 8.0 – 987.0 | 0 | - | |||
| 1:80 | 1# | 32.0 | 0 | - | ||||
| ARA | ||||||||
| Less than 1:20 | 99 | 29.0 | 4.0 – 1086.0 | 0.031* | 103 | 29.3 | 3.7 – 139.0 | - |
| 1:20 | 1# | 29.0 | 0 | - | ||||
| 1:40 | 2 | 7.0 | 6.0 – 8.0 | 0 | - | |||
| APCA | ||||||||
| Less than 1:20 | 84 | 29.0 | 6.0 – 1086.0 | 0.453 | 103 | 29.3 | 3.7 – 139.0 | - |
| 1:20 | 11 | 35.0 | 4.0 – 987.0 | 0 | - | |||
| 1:40 | 6 | 22.0 | 6.0 – 136.0 | 0 | - | |||
| 1:80 | 1# | 19.0 | 0 | - | ||||
| Anticanalicular | ||||||||
| Less than 1:20 | 94 | 29.0 | 5.0 – 1086.0 | 0.443 | 103 | 29.3 | 3.7 – 139.0 | - |
| 1:20 | 6 | 30.5 | 4.0 – 224.0 | 0 | - | |||
| 1:40 | 2 | 508 | 29.0 – 987.0 | 0 | - |
Abnormally distributed data was expressed in median (Min. - Max.); and was compared using Mann Whitney test;
*
Statistically significant at p ≤ 0.05